Retifanlimab

• PERELI - A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma Recruiting
  2022-501993-21-00 Phase II 3 countries Region Skane
• Study aimed at testing the activity of a course of chemo-immunotherapy with retifanlimab combined with platinum-etoposide followed by surger… Ended
  2024-516316-13-00 Phase II 1 country Fondazione GONO G.I.
• TORNADO : RANDOMIZED PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY PLUS RETIFANLIMAB (INCMGA00012) IN PATIENTS WITH SELECTED RETROPERITONEAL SA… Ended
  2023-509498-21-00 Phase II 1 country Institut Bergonie
• Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle… Ended
  2023-509380-24-00 Phase II 1 country Amsterdam UMC
• An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cance… Ended
  2022-502600-79-00 Phase II 4 countries Incyte Corp.
• A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TI… Ended
  2023-504270-38-00 Phase II 5 countries Incyte Biosciences International S.a.r.l.
• A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inop… Ended
  2024-512331-72-00 Phase III 8 countries Incyte Corp.
• A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and N… Ended
  2022-501987-16-00 Phase III 2 countries Incyte Corp.

Showing 1–8 of 8 trials